Is elagolix the same as Orilissa?
Orilissa is only available as a brand-name medication. It’s not available in a generic form. Orilissa contains the drug elagolix. Elagolix belongs to a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists.
What company makes Orilissa?
Discovered and developed through Phase II clinical trials by Neurocrine, ORILISSA™ (elagolix), the first FDA-approved oral medication for the management of endometriosis with associated moderate to severe pain in over a decade, is marketed by AbbVie as part of a collaboration to develop and commercialize elagolix for …
Does elagolix shrink fibroids?
Elagolix: approved to treat endometriosis and uterine fibroids. Elagolix stops a person’s ovaries from making estrogen and progesterone, which makes fibroids shrink, reduces menstrual bleeding, and diminishes pain.
Who makes elagolix?
4. AbbVie. AbbVie receives US FDA approval of ORILISSA™ (elagolix) for the management of moderate to severe pain associated with endometriosis.
Is elagolix a hormone?
Elagolix is the first approved oral gonadotropin-releasing hormone (GnRH) receptor antagonist for moderate to severe pain associated with endometriosis.
What does elagolix do?
Elagolix works by decreasing your body’s production of certain hormones (luteinizing hormone, follicle-stimulating hormone), which leads to lower amounts of female sex hormones (estrogens). These lower levels may help decrease some symptoms of endometriosis.
Is hair loss a side effect of Orilissa?
Menopause, weight loss, acne, and hair loss weren’t reported as side effects by people taking Orilissa in studies. Orilissa can cause amenorrhea (stopped periods), but this isn’t the same as menopause.
Is Orilissa a chemotherapy drug?
Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist (GnRH antagonist) medication which is used in the treatment of pain associated with endometriosis in women….Elagolix.
| Clinical data | |
|---|---|
| Trade names | Orilissa, Oriahn |
| Other names | NBI-56418, ABT-620 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618044 |
What is elagolix used for?
Elagolix is used to manage pain due to endometriosis (a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes infertility, pain before and during menstrual periods, pain during and after sexual activity, and heavy or irregular bleeding).
What pill is best for endometriosis?
There are various forms of synthetic progesterone called, “progestins” that are used to treat endometriosis. When treating young women, we prefer to start with a daily pill, such as a progesterone “birth control pill” sometimes referred to as a “mini-pill” or norethindrone acetate (Aygestin®).
What are the side effects of elagolix?
The most common side effects of ORILISSA include: hot flashes and night sweats, headache, nausea, difficulty sleeping, absence of periods, anxiety, joint pain, depression, and mood changes.
What happens when you go off Orilissa?
Stopped periods Taking Orilissa could cause your periods to stop as a side effect. You may also bleed less or for a shorter length of time during your periods.
What was the FDA approval for AbbVie elagolix?
AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis. The approval is supported by data from two replicate studies in the largest endometriosis Phase 3 study program conducted to date, which evaluated nearly 1,700 women with moderate to severe endometriosis pain.
Why did Neurocrine and AbbVie develop Orilissa?
“Neurocrine discovered ORILISSA nearly twenty years ago and through our partnership with AbbVie, the approval of ORILISSA reflects our joint commitment to develop therapies for difficult to manage conditions in underserved patient populations.”
Who is responsible for the development of elagolix?
ELAGOLIX DEVELOPMENT: ABBVIE COLLABORATION. In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s and men’s health. Under the terms of the agreement, AbbVie is responsible for future development and commercialization.
How does elagolix work to reduce pituitary GnRH?
Elagolix is a novel, orally administered gonadotropin-releasing hormone (GnRH) antagonist. Elagolix is believed to have its effect by altering the level of pituitary GnRH suppression and, as a result, titrating circulating hormone levels.